Tandem Diabetes (TNDM) Raises FY18 Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
Tandem Diabetes Care (TNDM) PT Raised to $57 at Oppenheimer
September 26, 2018 9:49 AM EDTOppenheimer analyst Steven Lichtman raised the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $57.00 (from $54.00) while maintaining an Outperform rating.
Lichtman commented, "Following a pre-announced 3Q18 beat and raised 2018 guidance, TNDM held its inaugural Investor and Analyst Day yesterday in CA. Management... More
